Brandenburg Kapital - News about Adrenomed AG
Milestone achieved in the clinical trial
Hennigsdorf/Berlin - December 2021. Adrenomed AG, portolio company of Brandenburg Kapital, announced that it has received positive feedback from the European Medicines Agency (EMA) regarding the clinical development program for its lead product candidate, Adrecizumab in indication of septic shock. This response is a positive signal and confirms the design of their forthcoming pivotal trial.
The first-in-class antibody targets the vasoprotective peptide adrenomedullin to restore vascular integrity in patients with early septic shock, a life-threatening condition with very limited treatment options.
The study results will serve as the fundament for the marketing authorization application for Adrecizumab in different regions. Further exchange with regulatory authorities is currently in preparation.
Brandenburg Kapital GmbH is invested in the company since 2014.
Read the complete press release in the attached download.
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to restore vascular integrity in order to save the lifes of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial in the indication of septic shock with 301 patients.
For further information, please visit www.adrenomed.com and www.brandenburg-kapital.de